USA - NASDAQ:NNOX - IL0011681371 - Common Stock
The current stock price of NNOX is 4.06 USD. In the past month the price increased by 9.14%. In the past year, price decreased by -29.76%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 12.92 | 103.91B | ||
| CI | THE CIGNA GROUP | 10.74 | 80.55B | ||
| LH | LABCORP HOLDINGS INC | 18.46 | 23.23B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.67 | 20.37B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 153.35 | 20.10B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.49 | 15.99B | ||
| HIMS | HIMS & HERS HEALTH INC | 60.98 | 11.03B | ||
| DVA | DAVITA INC | 13.33 | 9.24B | ||
| GH | GUARDANT HEALTH INC | N/A | 9.00B | ||
| RDNT | RADNET INC | 231.69 | 6.42B | ||
| CHE | CHEMED CORP | 19.52 | 6.36B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 45.31 | 5.94B |
Nano-X Imaging Ltd. engages in the development of medical imaging systems.
NANO-X IMAGING LTD
Ofer Tech Park, 94 Shlomo Shmeltzer Road
Petah Tikva 9085000 IL
CEO: Ran Poliakine
Employees: 165
Phone: 97237359202
Nano-X Imaging Ltd. engages in the development of medical imaging systems.
The current stock price of NNOX is 4.06 USD. The price decreased by -0.73% in the last trading session.
NNOX does not pay a dividend.
NNOX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
10 analysts have analysed NNOX and the average price target is 7.91 USD. This implies a price increase of 94.7% is expected in the next year compared to the current price of 4.06.
NANO-X IMAGING LTD (NNOX) operates in the Health Care sector and the Health Care Providers & Services industry.
The outstanding short interest for NANO-X IMAGING LTD (NNOX) is 10.31% of its float.
ChartMill assigns a technical rating of 1 / 10 to NNOX. When comparing the yearly performance of all stocks, NNOX is a bad performer in the overall market: 90.71% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to NNOX. NNOX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months NNOX reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 17.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.21% | ||
| ROE | -34.03% | ||
| Debt/Equity | 0 |
10 analysts have analysed NNOX and the average price target is 7.91 USD. This implies a price increase of 94.7% is expected in the next year compared to the current price of 4.06.
For the next year, analysts expect an EPS growth of -9.46% and a revenue growth 12.16% for NNOX